Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6371523 | 0.94 | SNCA (0.33) | SNCACTSSCTSK | |
| SCHEMBL7014387 | 0.91 | SNCA (0.33) | SNCACTSSCTSKALDH1A1MAPK1 | |
| SCHEMBL7419258 | 0.90 | CTSB (0.32) | CTSSCTSB | |
| SCHEMBL7418232 | 0.85 | PTGES (0.35) | — | |
| SCHEMBL7419503 | 0.85 | HSD11B1 (0.32) | ALDH1A1 | |
| SCHEMBL7411437 | 0.85 | CTSB (0.31) | CTSSCTSB | |
| SCHEMBL7422302 | 0.85 | SLC6A2 (0.35) | — | |
| SCHEMBL7414438 | 0.84 | PTGES (0.36) | ALDH1A1MAPK1 | |
| SCHEMBL7416244 | 0.84 | GPR132 (0.31) | ALDH1A1 | |
| SCHEMBL7416951 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218372-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001019816-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |